Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.50 -1.3% 38.00 336,520 16:35:12
Bid Price Offer Price High Price Low Price Open Price
37.50 39.00 38.25 38.25 38.25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 84.33 3.66 0.45 84.4 244
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:12 UT 46,000 38.00 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Investors    Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics (AGY) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 38.50p.
Allergy Therapeutics Plc has a 4 week average price of 32.60p and a 12 week average price of 24.50p.
The 1 year high share price is 38.50p while the 1 year low share price is currently 12.65p.
There are currently 640,792,164 shares in issue and the average daily traded volume is 575,469 shares. The market capitalisation of Allergy Therapeutics Plc is £243,501,022.32.
mighunter: AGY got second mention on Vox markets podcast with Vadim Alexandre. HTtps://www.voxmarkets.co.uk/articles/vadim-alexandre-discusses-polarean-imaging-allergy-therapeutics-41d8179/
jbuchanan1: How are they going to do the NASDAQ listing? Its mentioned in the RNS. Surely that will be good for the AIM share price. Any insight welcome. Thx
jimmyloser: This is todays Non RNS. The last paragraph is well worth digesting (impo) Allergy Therapeutics PLC 16 September 2021 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") ImmunoBON voted Most Innovative Product of 2021 at Pharma Trend Image and Innovation Awards in Germany 16 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, is pleased to announce that ImmunoBON, the Group's patented protein-based oral product for the general treatment of allergies, has been voted Most Innovative Product 2021 at the Pharma Trends Image and Innovation Awards in Germany. The awards, held every year, are based on the Pharma Trend benchmark study, which seeks the views of 700 physicians, 100 pharmacists and 600 patients in Germany. ImmunoBON, which Allergy Therapeutics launched in Germany and Austria earlier this year, replicates the reduced allergic reactions seen in people who live on or close to livestock farms - the so called 'farm effect'. It offers an innovative treatment approach for patients with mild allergies, the largest segment of the allergy market. Latest data support its use as a treatment for birch and house dust mite allergies and Allergy Therapeutics is currently exploring its potential across a broader patient population. Manuel Llobet, CEO of Allergy Therapeutics , stated: "We are delighted that ImmunoBON has been recognised for its innovative approach to the treatment of allergy patients, particularly as the award is voted for by those we serve - doctors, pharmacists and patients. "ImmunoBON is an exciting product that provides an over the counter (OTC) option which fits very well with our portfolio philosophy to develop highly differentiated products with specific value added for our patients. Following successful launches in Germany and Austria, we are looking forward to making ImmunoBON available to more patients, through additional country launches, and through research exploring its potential to treat additional allergies".
jimmyloser: Good news for those allergic to peanuts etc. Good news for AGY and it's talented team and good news for the faithful followers and believersCongratulations and Thanks AGYJl
catch007: Jimmyloser: Potential is exciting however what I really like is that there is a very solid underlying business here that is well capitalised and growing in its chosen markets. Peanuts, Grass and other initiatives are being self funded by AGY so progress will be reflected in share price Good long term hold
jimmyloser: I would suspect that many of both us long termers and recent investors are feeling rather pleased as we see the firming of the share price due to the excellent developments from the company. And (impo)so we should be, we do appear to be finally on the threshold of exciting developments both for those that are suffering badly with allergies and those with financial interest. Whilst it is very early days in the peanut development, the potential here is quite exceptional compared to what I have read of the competition. Then we have news on the horizon of Grass MATA MPL G309 which could well be a gamechanger and progress with immunoBON and let's not forget our innovative adjuvant technology. We have had our fair share of playing snakes and ladders here but the ladders are thankfully currently outnumbering the snakes. impo.
wapper: Well done all the team at AGY. This is a fantastic result.Shareholders will be rewarded well in medium term as AGY is not a one trick pony.
wizzkid211: Allergy Therapeutics PLC Successful primary outcome of VLP Peanut 001 August 03 2021 - 02:00AM UK Regulatory (RNS & others) Alert Print Share On Facebook TIDMAGY RNS Number : 3254H Allergy Therapeutics PLC 03 August 2021 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Allergy Therapeutics announces successful primary outcome of VLP Peanut 001; a study evaluating biomarkers from peanut allergic patients - Study results confirm peanut vaccine candidate's hypoallergic potential - Findings support VLP Peanut first in-human Phase I study design, on track to start Q1 2022 - Short-course peanut allergy vaccine candidate represents a significant opportunity in $8 billion worldwide food allergy market - Results strengthen Phase I study IND application being submitted to US FDA in late 2021 03 August 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces positive primary results from an ex-vivo biomarker study evaluating the Group's novel virus-like particle (VLP) based peanut allergy vaccine candidate ("VLP Peanut"). The study, which took place at Imperial College London, evaluated the Group's short-course VLP Peanut and aimed to demonstrate the vaccine candidate's hypoallergic potential. If a vaccine is hypoallergenic, it means it does not illicit an allergic reaction in patients upon dosing. The study used blood samples from peanut allergy patients to evaluate an extensive set of functional and molecular biomarkers. This resulted in a successful primary outcome, with the trial demonstrating a significant 24-fold reduction in basophil activation and histamine release after blood samples were challenged with VLP Peanut compared to a recombinant peanut extract, signifying the hypoallergenic potential of the vaccine candidate. These positive clinical data add to the Group's strong pre-clinical research package, which has demonstrated sustained immunologic protection following peanut exposure after just one single vaccination. The biomarker study results are encouraging and provide strong support for the human translation of the pre-clinical results and strong confidence in the data to be generated in the planned Phase I study (the PROTECT study). The data also provide important information to establish the starting dose for PROTECT, which is expected to commence in Q1 2022. Moreover, the results from this study further strengthen the Group's Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA), which is expected to be submitted in late 2021. Further data will be released in due course once secondary endpoints of the study have been analysed. In addition, the Group has also recently completed an extensive multiple dose toxicology study with VLP Peanut, applying the maximum subcutaneous doses expected to be administered in clinical trials, which further supports the dose escalations planned in the first in-human Phase I study. More information on VLP Peanut will be provided by the Group at a Key Opinion Leader investor event, currently planned for September 2021. VLP Peanut is being developed as a novel VLP-based therapy for the treatment of peanut allergy. This novel immunogenic, protective, and non-reactogenic vaccine candidate is based on immunologically optimised Cucumber Mosaic Virus-derived VLPs (CuMVTT) with the major peanut allergen (Arachis hypogaea) (Ara h 2) displayed on its surface. Patents behind the technology to treat peanut allergy with VLP Peanut have now been granted in the US and are at the national phase in other territories. The potential of an effective short-course peanut allergy vaccine represents a significant opportunity in the $8 billion worldwide food allergy market(1) . Peanut allergy is one of the most common types of food allergy and its symptoms can range from mild to severe and life-threatening. In the western world, the prevalence of peanut allergy doubled between 2005 and 2015 and it is becoming apparent in Africa and Asia(2) . Only about 20% of children diagnosed with peanut allergy outgrow it by the time they reach school age. In the US (as of 2014), peanut allergy was the most common cause of severe and fatal food-induced anaphylactic reactions(3) . Manuel Llobet, CEO of Allergy Therapeutics , stated: "We are pleased to have reached this important milestone in the development of our ground-breaking and disruptive vaccine candidate, VLP Peanut. Through our collaboration with Imperial College London and the dedication of our clinical and R&D teams at Allergy Therapeutics, we are another step closer to offering a potentially transformative treatment option for one of the most dangerous allergies. I am proud of the work we do in helping to transform patients' lives and look forward to our upcoming IND submission at the end of this year and expected initiation of our Phase I PROTECT trial in 2022." This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.
farmergeorge: Yes, pollen will also reach a 12 month high. Wonder if there's any correlation between AGY price and the pollen count ;-).
jimmyloser: You may recall that on December 23rd 2020 our share price and Futura Medicals were both trading neck and neck in low teens and I posted this................. 23 Dec '20 - 08:15 - 3945 of 4049 Edit As we approach the rag end of another trading year, I note that both AGY and FUM are trading at exactly the same price this morning. Both appear to hold products in their portfolio's that could well be a game changer in 2021. Perhap's this is harsh, but AGY seem to be permanently in the 'could' phase whilst FUM have time on their hands. I currently do not hold FUM, but for fun will buy some. Let's see where both are at, come the end of March! dyor/impo Now it is the end of March, three months and both have made progress. AGY now trading at 20/21p and Futura trading at 54p/56p as I type. They touched 80p! What a difference 13 weeks makes! I also said that I would buy some for fun. I didn't! dyor/impo
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210926 16:45:54